EW vs GEHC
Edwards Lifesciences and GE HealthCare, both Healthcare
Edwards Lifesciences is the larger company at $50B against $28B. On trailing earnings GEHC is the cheaper of the two at a P/E of 15.7 against 49.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +14% against -11% for GEHC.
| Figure | EW | GEHC |
|---|---|---|
| Last close | $85.20 | $65.73 |
| Market cap | $50B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 49.0 | 15.7 |
| Dividend yield | n/a | 0.2% |
| 1-year return | +14% | -11% |
| 5-year return | -29% | n/a |
| RyuScoresector-relative, 1–10 | 60/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 72% of the disclosed total.
GE HealthCare
Revenue of $5.1B in Q1 2026, net income $389M. Its largest reported line is AIS, 64% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.